
    
      The investigators investigate the change in the maxLCBI (4 mm) value calculated by NIRS-IVUS
      at the time of PCI and at the treatment evaluation after 9 months compared with the group of
      Alirocumab(Alirocumab75mg/2week+losuvastatin10mg/daily) and standard treatment
      (losuvastatin10mg/daily alone). And also the investigators evaluate LCBI(lesion), Angle of a
      lipid core, EEM CSA, Lumen CSA, Minimum lumen diameter, Plaque burden, Lesion length by
      NIRS-IVUS.
    
  